Journal
MOLECULAR PHARMACEUTICS
Volume 11, Issue 2, Pages 417-427Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp400366r
Keywords
cancer; C6 ceramide; curcumin; liposome; osteosarcoma
Funding
- Louisiana Cancer Research Consortium
- Louisiana Gene Therapy Research Consortium
- National Institutes of Health [CA151851]
- Department of Defense [W81XWH-10-1-0377]
Ask authors/readers for more resources
This study examines the antitumor potential of curcumin and C6 ceramide (C6) against osteosarcoma (OS) cell lines when both are encapsulated in the bilayer of liposomal nanoparticles. Three liposomal formulations were prepared: curcumin liposomes, C6 liposomes and C6-curcumin liposomes. Curcumin in combination with C6 showed 1.5 times enhanced cytotoxic effect in the case of MG-63 and KHOS OS cell lines, in comparison with curcumin liposomes alone. Importantly, C6-curcumin liposomes were found to be less toxic on untransformed primary human cells (human mesenchymal stem cells) in comparison to OS cell lines. In addition, cell cycle assays on a KHOS cell line after treatment revealed that curcumin only liposomes induced G(2)/M arrest by upregulation of cyclin B1, while C6 only liposomes induced G(1) arrest by downregulation of cyclin D1. C6-curcumin liposomes induced G(2)/M arrest and showed a combined effect in the expression levels of cyclin D1 and cyclin B1. The efficiency of the preparations was tested in vivo using a human osteosarcoma xenograft assay. Using pegylated liposomes to increase the plasma half-life and tagging with folate (FA) for targeted delivery in vivo, a significant reduction in tumor size was observed with C6-curcumin-FA liposomes. The encapsulation of two water insoluble drugs, curcumin and C6, in the lipid bilayer of liposomes enhances the cytotoxic effect and validates the potential of combined drug therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available